Overview

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

This phase II MATCH treatment trial tests how well erdafitinib (JNJ-42756493) works in treating patients with tumors that have FGFR mutations or fusions. Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. This may help keep cancer cells from growing and may kill them.

Phase:

PHASE2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Biopsy
erdafitinib
Magnetic Resonance Spectroscopy
Specimen Handling